Keystone Heart to Accelerate Trials for a New Advanced Cerebral Embolic Protection Device Post author:Sam Post published:August 1, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like “An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III February 13, 2018 FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration January 28, 2018 Ironwood Provides First Quarter 2017 Investor Update May 7, 2017
FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration January 28, 2018